Přejít k obsahu
Merck
Všechny fotografie(1)

Hlavní dokumenty

GE17-0618-05

Protein G Sepharose™ 4 Fast Flow

Cytiva 17-0618-05, pack of 200 mL

Synonyma:

Fast Flow resin, Antibody purification resin, IgG purification resin

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

UNSPSC Code:
41106500
NACRES:
NA.56

ligand

recombinant protein G lacking albumin-binding region

packaging

pack of 200 mL

manufacturer/tradename

Cytiva 17-0618-05

storage condition

(20% Ehtanol)

matrix

4% cross-linked agarose

average diameter

90 μm (d50v)

cleaning in place

2-10

working range

3-9

suitability

suitable for bioprocess medium

storage temp.

2-8°C

General description

Protein G Sepharose™ 4 Fast Flow is recombinant protein G coupled to Sepharose™ 4 Fast Flow.

Protein G Sepharose™ 4 Fast Flow has recombinant protein G immobilized by the cyanogen bromide (CNBr) method to Sepharose™ 4 Fast Flow. Protein G exhibit binding specificities that complement Protein A media and binds to the Fc region of IgG from a variety of mammalian species. Protein G Sepharose™ 4 Fast Flow may be used to isolate and purify classes, subclasses and fragments of immunoglobulins from any biological fluid or cell culture medium.

As member of the BioProcess media range, Protein G Sepharose™ 4 Fast Flow meets industrial demands with security of supply and comprehensive technical and regulatory support.

Features and Benefits

  • Binding specificities that complement Protein A media.
  • Binds a broad range of IgG species and subclasses.
  • Multi-point attachment minimizes ligand leakage.
  • Used in a range of research applications.

Storage and Stability

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.

Analysis Note

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

Legal Information

Sepharose is a trademark of Cytiva

pictograms

Flame
GHS02

signalword

Warning

hcodes

H226

Storage Class

3 - Flammable liquids

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Monique G P van der Wijst et al.
bioRxiv : the preprint server for biology (2021-03-25)
Type I interferon (IFN-I) neutralizing autoantibodies have been found in some critical COVID-19 patients; however, their prevalence and longitudinal dynamics across the disease severity scale, and functional effects on circulating leukocytes remain unknown. Here, in 284 COVID-19 patients, we found
Kanika Vanshylla et al.
Cell host & microbe, 29(6), 917-929 (2021-05-14)
Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4%
Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.
Sara E Vazquez et al.
Journal of clinical immunology, 41(6), 1169-1171 (2021-05-20)
Kanika Vanshylla et al.
Cell host & microbe, 30(1), 69-82 (2022-01-02)
A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we performed single B cell analysis from 10 SARS-CoV-2 elite neutralizers. We isolated and analyzed 126
Monique G P van der Wijst et al.
Science translational medicine, 13(612), eabh2624-eabh2624 (2021-08-26)
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynamics across
Zobrazit všechny související dokumenty

Sortimentní položky

Performing a Separation with HiTrap® Protein G HP

Purify monoclonal or polyclonal IgG from serum, cell culture supernatant or ascitic fluid using the HiTrap Protein G HP from Cytiva, an affinity-exclusion chromatography product containing Sepharose-immobilized Protein G.

Immunoprecipitation Techniques

This page describes immunoprecipitation (immunoaffinity or pull-down techniques).

Column Packing and Preparation for Affinity Chromatography of Antibodies

This page describes efficient column packing and preparation for affinity chromatography of antibodies.

Převod z rychlosti proudění na objemové průtoky

Tato stránka ukazuje, jak převést průtokovou rychlost na objemový průtok při afinitní chromatografii protilátek.

Zobrazit všechny

Protokoly

Pull-down assays

This page provides information about different pull-down assays for the further isolation of multiprotein complexes to identify their components with products from Cytiva.

Testy vytahováním

Tato stránka poskytuje informace o různých pull-down testech pro další izolaci multiproteinových komplexů za účelem identifikace jejich složek pomocí produktů společnosti Cytiva.

Performing a Purification of IgG Antibodies with Protein G Sepharose® 4 Fast Flow

This page shows how to separate IgG antibodies by affinity chromatography using Protein G Sepharose 4 Fast Flow from Cytiva.

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.